CME Presentations

Nasal Polyps Management



  • Kathleen Buchheit, MD

    Kathleen Buchheit, MD

    Kathleen Buchheit, MD

    Assistant Professor of Medicine

    Katie Buchheit, MD, is the assistant director of the AERD Center at the Brigham and Women’s Hospital (BWH) in Boston, Massachusetts. Her research focuses on understanding aspirin-exacerbated respiratory disease (AERD) and nasal polyposis. She is dedicated to investigating the causative mechanisms and exploring new treatments for these diseases. Dr. Buchheit is principal investigator of an NIH-funded study investigating the role of B cells and plasma cells in the pathogenesis of AERD and nasal polyps, as well as the mechanistic factors associated with nasal polyp recurrence. Clinically, she primarily focuses on the treatment of patients with chronic rhinosinusitis and AERD. During her allergy/immunology fellowship at BWH, she focused on the pathogenesis of nasal polyposis and AERD.
  • Stella Lee, MD

    Stella Lee, MD

    Stella Lee, MD

    Director of the Brigham Sinus Center

    Stella Lee, MD is a fellowship-trained rhinologist and chief of rhinology at Brigham and Women’s Hospital (BWH)/Harvard Medical School in Boston, Massachusetts. She is a clinician scientist developing novel management strategies for the care of patients with inflammatory upper airway disease and is a leader in developing therapeutics for airway inflammation. Before joining BWH, Dr. Lee was the division chief for sino-nasal disorders and allergy in the Department of Otolaryngology at the University of Pittsburgh Medical Center for ten years. Her research interests include defining inflammatory endotypes of chronic rhinosinusitis, the impact of environmental pollution on airway inflammation, and the development of basic to translational approaches to solve chronic inflammation.

CME Information

Global Logo PQH Logo
Caring for Patients with Nasal Polyps in 2023: When to Consider a Biologic or Surgery?
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Asthma and Allergy Foundation of America (AAFA)


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.


This activity was released on August 24th, 2023 and is valid until October 24, 2024. Requests for credit must be made no later than October 24th, 2024


The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps (NPs).


In a recent outcomes survey of patients with nasal polyps (NPs), 88% responded that their treatment journey had been extremely burdensome and that lack of communication with their care team was a barrier to proper diagnoses or changes in therapeutic approaches. With increased awareness of newer, more effective treatments, frontline clinicians who manage NPs and chronic rhinosinusitis with nasal polyposis (CRSwNP) can help alleviate patients’ disease burden related to inadequate symptom control and recurrent disease.

Join an expert panel of allergy and ENT specialists to review the latest understanding of NPs and CRSwNP, including severe NPs and those at high risk for recurrence. Panelists will clarify the place of functional endoscopic sinus surgery (FESS) and biologic agents in the treatment of CRSwNP. After participating in the education, clinician participants will recognize biologics available to treat NPs and understand which patient characteristics justify their use. Participating allergists ENTs will also be prepared to collaborate in the care of patients with NPs and include them in effective, shared decisions about treatment.


After completing this activity, the participant should be better able to:
  • Summarize the burden of disease and treatment for people with NPs, with a focus on outcomes that matter to patients, such as ability to smell, sleep, and be productive
  • Describe the T2 inflammatory relationships between NPs and common comorbidities, such as asthma, aspirin-exacerbated respiratory disease (AERD), and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD)
  • Explain how enhanced knowledge of NP endotypes and T2 inflammatory pathways can guide treatment decisions
  • Review recent recommendations for the management of NPs with surgery and monoclonal antibodies, especially as they apply to the management of uncontrolled, severe NPs


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 90 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Stella Lee, MD
Director of the Brigham Sinus Center
Brigham and Women's Hospital
Consulting Fee (e.g., Advisory Board): AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron
Kathleen Buchheit, MD
Assistant Professor of Medicine
Brigham and Women's Hospital
Consulting Fee (e.g., Advisory Board): AstraZeneca, Regeneron, Sanofi, GSK
Honoraria: GSK

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities


Physician Accreditation Support:

For information about the physician accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at